CV Therapeutics said it would ‘review developments in the context of the company’s strategic plans’ after Japanese drug company Astellas sought to revive a previously rejected takeover proposal.
More: continued here
CV Therapeutics said it would ‘review developments in the context of the company’s strategic plans’ after Japanese drug company Astellas sought to revive a previously rejected takeover proposal.
More: continued here